Enveric Biosciences Inc
ENVB4.640USD
-0.030-0.64%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
200.41KMarket Cap
LossP/E TTM
More Details of Enveric Biosciences Inc Company
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Enveric Biosciences Inc Info
Ticker SymbolENVB
Company nameEnveric Biosciences Inc
IPO dateJul 21, 2009
CEOTucker (Joseph)
Number of employees5
Security typeOrdinary Share
Fiscal year-endJul 21
Address245 First Street Riverview Ii 18Th Floor
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone12393021707
Websitehttps://www.enveric.com/
Ticker SymbolENVB
IPO dateJul 21, 2009
CEOTucker (Joseph)
Company Executives of Enveric Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Frank Pasqualone
Mr. Frank Pasqualone
Independent Director
Independent Director
271.00
--
Dr. Marcus Schabacker, M.D., Ph.D.
Dr. Marcus Schabacker, M.D., Ph.D.
Independent Director
Independent Director
267.00
--
Mr. Michael D. Webb
Mr. Michael D. Webb
Independent Chairman of the Board
Independent Chairman of the Board
265.00
--
Dr. Joseph Tucker, Ph.D.
Dr. Joseph Tucker, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Kevin M. Coveney
Mr. Kevin M. Coveney
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Peter Facchini, Ph.D.
Dr. Peter Facchini, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
Mr. George Kegler
Mr. George Kegler
Independent Director
Independent Director
--
--
Dr. Sheila H DeWitt, Ph.D.
Dr. Sheila H DeWitt, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Irish
Mr. David Irish
Investor Relations Officer
Investor Relations Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Frank Pasqualone
Mr. Frank Pasqualone
Independent Director
Independent Director
271.00
--
Dr. Marcus Schabacker, M.D., Ph.D.
Dr. Marcus Schabacker, M.D., Ph.D.
Independent Director
Independent Director
267.00
--
Mr. Michael D. Webb
Mr. Michael D. Webb
Independent Chairman of the Board
Independent Chairman of the Board
265.00
--
Dr. Joseph Tucker, Ph.D.
Dr. Joseph Tucker, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Kevin M. Coveney
Mr. Kevin M. Coveney
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Peter Facchini, Ph.D.
Dr. Peter Facchini, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 13
Updated: Sat, Dec 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ayrton Capital LLC
4.08%
AdvisorShares Investments, LLC
2.84%
UBS Financial Services, Inc.
1.47%
Orca Capital GmbH
1.35%
Geode Capital Management, L.L.C.
0.46%
Other
89.80%
Shareholders
Shareholders
Proportion
Ayrton Capital LLC
4.08%
AdvisorShares Investments, LLC
2.84%
UBS Financial Services, Inc.
1.47%
Orca Capital GmbH
1.35%
Geode Capital Management, L.L.C.
0.46%
Other
89.80%
Shareholder Types
Shareholders
Proportion
Investment Advisor
5.69%
Hedge Fund
4.43%
Investment Advisor/Hedge Fund
0.46%
Individual Investor
0.45%
Other
88.97%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
32
35.93K
4.70%
--
2025Q3
33
35.93K
9.00%
+8.33K
2025Q2
36
27.60K
11.29%
-1.59K
2025Q1
34
29.19K
3.74%
+21.48K
2024Q4
32
6.00K
10.16%
+2.04K
2024Q3
32
3.95K
9.27%
+1.14K
2024Q2
40
2.81K
10.39%
+95.00
2024Q1
47
2.72K
7.53%
-343.00
2023Q4
48
2.72K
14.50%
+1.48K
2023Q3
48
1.24K
12.54%
+178.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AdvisorShares Investments, LLC
203.68K
6.27%
+100.00K
+96.45%
Sep 30, 2025
UBS Financial Services, Inc.
27.34K
0.84%
-15.42K
-36.07%
Jun 30, 2025
Orca Capital GmbH
97.02K
2.99%
+97.02K
--
Jan 31, 2025
Geode Capital Management, L.L.C.
28.16K
0.87%
+1.60K
+6.03%
Jun 30, 2025
Tucker (Joseph Edward)
103.76K
3.2%
+98.87K
+2020.97%
May 08, 2025
Coveney (Kevin Michael)
76.28K
2.35%
+74.15K
+3476.32%
May 08, 2025
Facchini (Peter James)
27.44K
0.85%
+24.72K
+906.38%
May 08, 2025
Pasqualone (Frank)
3.25K
0.1%
--
--
Apr 11, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
0.56%
AdvisorShares Psychedelics ETF
Proportion0.56%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 23, 2025
Merger
12→1
Jan 21, 2025
Merger
15→1
Jan 21, 2025
Merger
15→1
Jan 21, 2025
Merger
15→1
Jan 21, 2025
Merger
15→1
Jul 14, 2022
Merger
50→1
Date
Type
Ratio
Oct 23, 2025
Merger
12→1
Jan 21, 2025
Merger
15→1
Jan 21, 2025
Merger
15→1
Jan 21, 2025
Merger
15→1
Jan 21, 2025
Merger
15→1
Jul 14, 2022
Merger
50→1
Jul 14, 2022
Merger
50→1
Jul 14, 2022
Merger
50→1
Jul 14, 2022
Merger
50→1
Dec 30, 2020
Merger
4→1
View more
FAQs
Who are the top five shareholders of Enveric Biosciences Inc?
The top five shareholders of Enveric Biosciences Inc are:
AdvisorShares Investments, LLC holds 203.68K shares, accounting for 6.27% of the total shares.
UBS Financial Services, Inc. holds 27.34K shares, accounting for 0.84% of the total shares.
Orca Capital GmbH holds 97.02K shares, accounting for 2.99% of the total shares.
Geode Capital Management, L.L.C. holds 28.16K shares, accounting for 0.87% of the total shares.
Tucker (Joseph Edward) holds 103.76K shares, accounting for 3.20% of the total shares.
AdvisorShares Investments, LLC holds 203.68K shares, accounting for 6.27% of the total shares.
UBS Financial Services, Inc. holds 27.34K shares, accounting for 0.84% of the total shares.
Orca Capital GmbH holds 97.02K shares, accounting for 2.99% of the total shares.
Geode Capital Management, L.L.C. holds 28.16K shares, accounting for 0.87% of the total shares.
Tucker (Joseph Edward) holds 103.76K shares, accounting for 3.20% of the total shares.
What are the top three shareholder types of Enveric Biosciences Inc?
The top three shareholder types of Enveric Biosciences Inc are:
Ayrton Capital LLC
AdvisorShares Investments, LLC
UBS Financial Services, Inc.
Ayrton Capital LLC
AdvisorShares Investments, LLC
UBS Financial Services, Inc.
How many institutions hold shares of Enveric Biosciences Inc (ENVB)?
As of 2025Q4, 32 institutions hold shares of Enveric Biosciences Inc, with a combined market value of approximately 35.93K, accounting for 4.70% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.30%.
What is the biggest source of revenue for Enveric Biosciences Inc?
In --, the -- business generated the highest revenue for Enveric Biosciences Inc, amounting to -- and accounting for --% of total revenue.
